250 related articles for article (PubMed ID: 29925418)
1. DNA damage repair in ovarian cancer: unlocking the heterogeneity.
Gee ME; Faraahi Z; McCormick A; Edmondson RJ
J Ovarian Res; 2018 Jun; 11(1):50. PubMed ID: 29925418
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
3. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
4. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract][Full Text] [Related]
5. The changing view of high-grade serous ovarian cancer.
Berns EM; Bowtell DD
Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
[TBL] [Abstract][Full Text] [Related]
6. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT; Drapkin R
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
[TBL] [Abstract][Full Text] [Related]
8. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies.
Mirza-Aghazadeh-Attari M; Ostadian C; Saei AA; Mihanfar A; Darband SG; Sadighparvar S; Kaviani M; Samadi Kafil H; Yousefi B; Majidinia M
DNA Repair (Amst); 2019 Aug; 80():59-84. PubMed ID: 31279973
[TBL] [Abstract][Full Text] [Related]
10. Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
Schildkraut JM; Iversen ES; Wilson MA; Clyde MA; Moorman PG; Palmieri RT; Whitaker R; Bentley RC; Marks JR; Berchuck A
PLoS One; 2010 Apr; 5(4):e10061. PubMed ID: 20386703
[TBL] [Abstract][Full Text] [Related]
11. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
Ovejero-Sánchez M; González-Sarmiento R; Herrero AB
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672401
[TBL] [Abstract][Full Text] [Related]
13. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
[TBL] [Abstract][Full Text] [Related]
14. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
[TBL] [Abstract][Full Text] [Related]
20. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis.
Fuseya C; Horiuchi A; Hayashi A; Suzuki A; Miyamoto T; Hayashi T; Shiozawa T
Hum Pathol; 2012 Nov; 43(11):1964-72. PubMed ID: 22626277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
